Faith-based organization management platform provider Gloo (GLOO.US) plans to price its IPO at $10-12 per share, aiming to raise $100 million.
Gloo Holdings, a company that provides management and marketing platforms for religious organizations, plans to issue 9.1 million shares of stock at a price of $10-12 per share, raising $100 million.
The company Gloo Holdings, which provides management and marketing platforms for religious organizations, announced its IPO terms on Thursday. The company plans to issue 9.1 million shares of stock at a price of $10 - $12 per share, raising $100 million. Based on the midpoint of the proposed offering price range, Gloo Holdings' market value will reach $801 million.
Gloo Holdings provides a vertical platform for faith-based organizations, with a focus on churches and Christian organizations. Its products include the enterprise subscription platform Gloo360, which offers cloud services, IT hosting, network security, business intelligence, and consulting; the all-in-one communication, content, and interaction tool Gloo Workspace; the e-commerce marketplace Outreach; and the advertising and donor engagement suite Gloo Media Network. As of July 31, 2025, the company has around 57,000 paying customers.
Founded in 2013, Gloo Holdings had revenue of $41 million in the 12 months leading up to July 31, 2025. The company plans to list on the Nasdaq under the ticker symbol GLOO. Roth Capital is the sole book-running manager for this transaction. The company is expected to price its IPO during the week of November 17, 2025.
Related Articles

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.
.png)
Zejing Pharmaceutical (688266.SH): Gicacizidine hydrochloride tablets included in the 2025 National Medical Insurance Drug List.
HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.

Zejing Pharmaceutical (688266.SH): Gicacizidine hydrochloride tablets included in the 2025 National Medical Insurance Drug List.
.png)





